• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study supports use of PharmaJet’s needle-free vaccine delivery systems

April 27, 2022 By Sean Whooley

PharmaJet Stratis
The PharmaJet Stratis system. [Image from PharmaJet]
PharmaJet announced today that study data demonstrated increased immunogenicity when using its needle-free delivery system.

Golden, Colorado-based PharmaJet presented the research results for the needle-free vaccine injection technology last week at the World Vaccine Congress.

PharmaJet’s needle-free systems have been incorporated into clinical studies for multiple RNA and DNA vaccine and therapeutic development programs thanks to collaborations with more than 50 pharmaceutical partners, the company said in a news release.

Increased immunogenicity was seen in the Phase 3 interim clinical trial of Zydus’ Lifesciences’ plasmid DNA vaccine for protection against COVID-19 when administered intradermally with PharmaJet’s Tropis system.

Data also demonstrated an increased antibody response for an influenza heterologous prime-boost vaccination regimen consisting of an initial DNA vaccination delivered with PharmaJet’s Stratis intramuscular/subcutaneous system, followed by a ferritin nanoparticle vaccination. The Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health study demonstrated higher binding and neutralizing antibodies with the regimen.

A U.S. Army Medical Research Institute of Infectious Diseases study used the Stratis system to test Andes and Zika virus DNA vaccines in lipid nanoparticle (LNP) formulations and administered them to rabbits, non-human primates and bovine. The outcomes included a fast and high antibody titer response compared to the same unformulated vaccines, showing the feasibility of using bovine to produce antibodies for future passive immunotherapy use in people.

“The PharmaJet Needle-free injection technology continues to show robust safety and overwhelmingly positive clinical efficacy with both commercial and pipeline vaccines and pharmaceuticals,” PharmaJet President and CEO Chris Cappello said in the release. “An increasing amount of data is showing superior efficacy over other delivery methods with nucleic acid-based platforms for vaccines, therapeutics, and personalized medicine.”

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Pharmaceuticals Tagged With: PharmaJet

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS